| 臺大學術典藏 |
2021-02-02T05:45:19Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.;Bair M.-J.;Chen C.-C.;Yi-Chia Lee;Chen M.-J.;Chen C.-C.;Tseng C.-H.;Fang Y.-J.;Lee J.-Y.;Yang T.-H.;Luo J.-C.;Wu J.-Y.;Chang W.-H.;Chang C.-C.;Chen C.-Y.;Chen P.-Y.;Shun C.-T.;Hsu W.-F.;Hung H.-W.;Lin J.-T.;Chang C.-Y.;Wu M.-S.; Liou J.-M.; Bair M.-J.; Chen C.-C.; YI-CHIA LEE; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2021-02-02T05:45:19Z |
Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection
|
Chen M.-J.;Liou J.-M.;Chen C.-C.;Yi-Chia Lee;Chang C.-Y.;Wu J.-Y.;Bair M.-J.;Lin J.-T.;Wu M.-S.; Chen M.-J.; Liou J.-M.; Chen C.-C.; YI-CHIA LEE; Chang C.-Y.; Wu J.-Y.; Bair M.-J.; Lin J.-T.; Wu M.-S. |
| 臺大學術典藏 |
2021-02-02T05:45:16Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.;Chen C.-C.;Chang C.-Y.;Chen M.-J.;Chen C.-C.;Fang Y.-J.;Lee J.-Y.;Yang T.-H.;Luo J.-C.;Wu J.-Y.;Liou T.-C.;Chang W.-H.;Hsu Y.-C.;Tseng C.-H.;Chang C.-C.;Bair M.-J.;Liu T.-Y.;Hsieh C.-F.;Tsao F.-Y.;Shun C.-T.;Lin J.-T.;Yi-Chia Lee;Wu M.-S.;The Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; YI-CHIA LEE; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:15Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.;Fang Y.-J.;Chen C.-C.;Bair M.-J.;Chang C.-Y.;Yi-Chia Lee;Chen M.-J.;Chen C.-C.;Tseng C.-H.;Hsu Y.-C.;Lee J.-Y.;Yang T.-H.;Luo J.-C.;Chang C.-C.;Chen C.-Y.;Chen P.-Y.;Shun C.-T.;Hsu W.-F.;Hu W.-H.;Chen Y.-N.;Sheu B.-S.;Lin J.-T.;Wu J.-Y.;El-Omar E.M.;Wu M.-S.;Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; YI-CHIA LEE; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:09Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; YI-CHIA LEE; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:08Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; YI-CHIA LEE; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Wu M.-S.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:02Z |
Planning mass eradication of Helicobacter pylori infection for indigenous Taiwanese peoples to reduce gastric cancer
|
Bair M.-J.;Chuang S.-L.;Lei W.-Y.;Chen C.-L.;Tian H.-W.;Chiang T.-H.;Su W.W.-Y.;Lin C.-C.;Chung Lo Y.-T.;Jou Y.-Y.;Wu C.-Y.;Chia S.-L.;Wu M.-S.;Chen H.-H.;Chu C.-H.;Yi-Chia Lee;Wang Y.-W.; Bair M.-J.; Chuang S.-L.; Lei W.-Y.; Chen C.-L.; Tian H.-W.; Chiang T.-H.; Su W.W.-Y.; Lin C.-C.; Chung Lo Y.-T.; Jou Y.-Y.; Wu C.-Y.; Chia S.-L.; Wu M.-S.; Chen H.-H.; Chu C.-H.; YI-CHIA LEE; Wang Y.-W. |
| 臺大學術典藏 |
2021-02-02T03:08:06Z |
Planning mass eradication of Helicobacter pylori infection for indigenous Taiwanese peoples to reduce gastric cancer
|
Bair M.-J.; Chuang S.-L.; Lei W.-Y.; Chen C.-L.; Tian H.-W.; TSUNG-HSIEN CHIANG; Su W.W.-Y.; Lin C.-C.; Chung Lo Y.-T.; Jou Y.-Y.; Wu C.-Y.; Chia S.-L.; Wu M.-S.; Chen H.-H.; Chu C.-H.; Lee Y.-C.; Wang Y.-W. |
| 臺大學術典藏 |
2021-02-02T02:25:00Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; MING-SHIANG WU; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; MING-SHIANG WU; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:58Z |
Spontaneous clearance of Helicobacter pylori colonization in patients with partial gastrectomy: Correlates with operative procedures and duration after operation
|
Bair M.-J.; MING-SHIANG WU; Chang W.-H.; Shih S.-C.; Wang T.-E.; Chen C.-J.; Lin C.-C.; Liu C.-Y.; Chen M.-J. |
| 臺大學術典藏 |
2021-02-02T02:21:57Z |
Abdominal tuberculosis in Southeastern Taiwan: 20 years of experience
|
Chen H.-L.; MING-SHIANG WU; Chang W.-H.; Shih S.-C.; Chi H.; Bair M.-J. |
| 臺大學術典藏 |
2021-02-02T02:21:53Z |
Prevalence of Helicobacter pylori Infection in High-school Students on Lanyu Island, Taiwan: Risk Factor Analysis and Effect on Growth
|
Chi H.; Bair M.-J.; MING-SHIANG WU; Chiu N.-C.; Hsiao Y.-C.; Chang K.-Y. |
| 臺大學術典藏 |
2021-02-02T02:21:28Z |
Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease
|
Hu K.-C.; Wang H.-Y.; Liu S.-C.; Liu C.-C.; Hung C.-L.; Bair M.-J.; Liu C.-J.; MING-SHIANG WU; Shih S.-C. |
| 臺大學術典藏 |
2021-02-02T02:21:19Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; MING-SHIANG WU; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:14Z |
Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection
|
Chen M.-J.; Liou J.-M.; Chen C.-C.; Lee Y.-C.; Chang C.-Y.; Wu J.-Y.; Bair M.-J.; Lin J.-T.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:14Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:10Z |
Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection
|
Chen P.-Y.; MING-SHIANG WU; Chen C.-Y.; Bair M.-J.; Chou C.-K.; Lin J.-T.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:08Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; MING-SHIANG WU; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:08Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:07Z |
Hyperglycemia combined Helicobacter pylori infection increases risk of synchronous colorectal adenoma and carotid artery plaque
|
Hu K.-C.; MING-SHIANG WU; Chu C.-H.; Wang H.-Y.; Lin S.-C.; Po H.L.; Bair M.-J.; Liu C.-C.; Su T.-H.; Chen C.-L.; Liu C.-J.; Shih S.-C. |
| 臺大學術典藏 |
2021-02-02T02:21:01Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; MING-SHIANG WU; Chen C.-C.; Chen C.-C.; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:53Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:53Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; MING-SHIANG WU; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; MING-SHIANG WU; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:47Z |
Helicobacter pylori infection combined with non-alcoholic fatty liver disease increase the risk of atherosclerosis: Focus in carotid artery plaque
|
Yu L.-Y.; Hu K.-C.; Liu C.-J.; Hung C.-L.; Bair M.-J.; Chen M.-J.; Wang H.-Y.; MING-SHIANG WU; Shih S.-C.; Liu C.-C. |
| 臺大學術典藏 |
2021-02-02T02:20:43Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:41Z |
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan
|
Chen M.-J.; Fang Y.-J.; MING-SHIANG WU; Chen C.-C.; Chen Y.-N.; Yu C.-C.; Kuo C.-C.; Chiu M.-C.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen H.-H.; Bair M.-J.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:41Z |
Planning mass eradication of Helicobacter pylori infection for indigenous Taiwanese peoples to reduce gastric cancer
|
Bair M.-J.; Chuang S.-L.; Lei W.-Y.; Chen C.-L.; Tian H.-W.; Chiang T.-H.; Su W.W.-Y.; Lin C.-C.; Chung Lo Y.-T.; Jou Y.-Y.; Wu C.-Y.; Chia S.-L.; MING-SHIANG WU; Chen H.-H.; Chu C.-H.; Lee Y.-C.; Wang Y.-W. |
| 臺大學術典藏 |
2021-02-02T02:20:39Z |
Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan
|
Fang Y.-J.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Yu C.-C.; Chiu M.-C.; Kuo C.-C.; Weng Y.-J.; Bair M.-J.; MING-SHIANG WU; Luo J.-C.; Liou J.-M. |
| 臺大學術典藏 |
2021-01-15T03:46:42Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; HSIU-PO WANG; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-01-15T03:46:28Z |
Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment a digestive endoscopy society of tawian (dest)
|
Chung C.-S.; Tsai C.-L.; Chu Y.-Y.; Chen K.-C.; Lin J.-C.; Chen B.-C.; Sun W.-C.; Yen H.-H.; Chen C.-Y.; Wu I.-C.; Kuo C.-H.; Shih H.-Y.; Bair M.-J.; Wang J.P.; Hu W.-H.; Yang C.-S.; Han M.-L.; Cheng T.-Y.; Tseng C.-M.; Tsai M.-C.; Hu M.-L.; HSIU-PO WANG |
| 國立成功大學 |
2021 |
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
|
Huang, C.-F.;Kuo, H.-T.;Chang, T.-S.;Lo, C.-C.;Hung, C.-H.;Huang, C.-W.;Chong, L.-W.;Cheng, P.-N.;Yeh, M.-L.;Peng, C.-Y.;Cheng, Cheng C.-Y.;Huang, J.-F.;Bair, M.-J.;Lin, C.-L.;Yang, C.-C.;Wang, S.-J.;Hsieh, T.-Y.;Lee, T.-H.;Lee, P.-L.;Wu, Wu W.-C.;Lin, C.-L.;Su, W.-W.;Yang, S.-S.;Wang, C.-C.;Hu, J.-T.;Mo, L.-R.;Chen, Chen C.-T.;Huang, Y.-H.;Chang, Chang C.-C.;Huang, C.-S.;Chen, G.-Y.;Kao, C.-N.;Tai, C.-M.;Liu, C.-J.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Kao, J.-H.;Lin, H.-C.;Chuang, W.-L.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Yeh, M.-L.;Hung, C.-H.;Tseng, K.-C.;Lai, H.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Yang, C.-C.;Lo, G.-H.;Tai, C.-M.;Lin, C.-W.;Kao, J.-H.;Liu, C.-H.;Yan, S.-L.;Bair, M.-J.;Lin, C.-Y.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Tung, S.-Y.;Lo, C.-C.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Huang, C.-F.;Huang, J.-F.;Dai, C.-Y.;Chuang, W.-L.;Tsai, P.-C.;Peng, C.-Y.;Liu, C.-J.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
|
Hsieh, M.-H.;Bair, M.-J.;Tsai, P.-C.;Tseng, K.-C.;Lo, C.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Hung, C.-H.;Lai, H.-C.;Peng, C.-Y.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Yang, C.-C.;Lo, G.-H.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Yan, S.-L.;Lin, C.-Y.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Tung, S.-Y.;Tai, C.-M.;Lin, C.-W.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Yeh, M.-L.;Huang, C.-F.;Huang, J.-F.;Dai, C.-Y.;Yu, M.-L.;Chuang, W.-L.;investigators, T-COACH |
| 國立成功大學 |
2021 |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen, Chen C.-Y.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Lo, C.-C.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)
|
Hsu, W.-F.;Tsai, P.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Lai, H.-C.;Kuo, H.-T.;Hung, C.-H.;Tung, S.-Y.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Lin, C.-Y.;Yang, C.-C.;Lo, G.-H.;Tai, C.-M.;Lin, C.-W.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Yan, S.-L.;Bair, M.-J.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Lo, C.-C.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Huang, J.-F.;Dai, C.-Y.;Chuang, W.-L.;Yu, M.-L.;Peng, C.-Y. |
| 臺大學術典藏 |
2020-11-27T03:28:39Z |
Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection
|
Chen M.-J.; Liou J.-M.; CHIEH-CHANG CHEN; Lee Y.-C.; Chang C.-Y.; Wu J.-Y.; Bair M.-J.; Lin J.-T.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:39Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; CHIEH-CHANG CHEN; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Tsao F.-Y.; Liu T.-Y.; Hsieh C.-F.; Bair M.-J.; Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-Y.; Chen M.-J.; Chien-Chuan Chen; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C. |
| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; CHIEH-CHANG CHEN; Lee Y.-C.; Chen M.-J.; Chien-Chuan Chen; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:37Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; CHIEH-CHANG CHEN; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chien-Chuan Chen; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; Chien-Chuan Chen; CHIEH-CHANG CHEN; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:35Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; CHIEH-CHANG CHEN; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chun-Chao Chang; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Wu M.-S.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:33Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chien-Chuan Chen; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:32Z |
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan
|
Chen M.-J.; Fang Y.-J.; Wu M.-S.; CHIEH-CHANG CHEN; Chen Y.-N.; Yu C.-C.; Kuo C.-C.; Chiu M.-C.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen H.-H.; Bair M.-J.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:32Z |
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial
|
CHIEH-CHANG CHEN; Luo J.-C.; Fang Y.-J.; Lee J.-Y.; Kuo C.-C.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Bair M.-J.; Chen P.-Y.; Chou C.-K.; Chen C.-Y.; Chang C.-Y.; Hsu Y.-C.; Tseng C.-H.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen M.-J.; Shun C.-T.; Liu T.-Y.; Lee§ Y.-C.; Liou§ J.-M.; Wu§ M.-S.; and for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:31Z |
Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan
|
Fang Y.-J.; Chen M.-J.; CHIEH-CHANG CHEN; Lee J.-Y.; Yang T.-H.; Yu C.-C.; Chiu M.-C.; Kuo C.-C.; Weng Y.-J.; Bair M.-J.; Wu M.-S.; Luo J.-C.; Liou J.-M. |
| 臺大學術典藏 |
2020-11-19T03:19:10Z |
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection
|
Lin C.-W.;Chen Y.-S.;Lin C.-C.;Po-Huang Lee;Lo G.-H.;Hsu C.-C.;Hsieh P.-M.;Koh K.W.;Bair M.-J.;Dai C.-Y.;Huang J.-F.;Chuang W.-L.;Chen Y.-L.;Yu M.-L.; Yu M.-L.; Chen Y.-L.; Chuang W.-L.; Huang J.-F.; Lin C.-W.; Chen Y.-S.; Lin C.-C.; PO-HUANG LEE; Lo G.-H.; Hsu C.-C.; Hsieh P.-M.; Koh K.W.; Bair M.-J.; Dai C.-Y. |
| 臺大學術典藏 |
2020-11-03T08:19:40Z |
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; Liu C.-J.; CHEN-HUA LIU; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L.; Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H. |
| 臺大學術典藏 |
2020-11-03T08:19:39Z |
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis
|
Peng C.-Y.; Yu M.-L.; Chuang W.-L.; Dai C.-Y.; Huang J.-F.; Huang Y.-H.; Tsai P.-C.; Tsai W.-L.; Lin H.-C.; Cheng J.-S.; Wang C.-C.; Chiu Y.-C.; Cheng P.-N.; Lo C.-C.; Chen C.-J.; Chu C.-H.; Su W.-W.; Bair M.-J.; Yan S.-L.; CHEN-HUA LIU; Liu C.-J.; Lin C.-W.; Kao J.-H.; Tai C.-M.; Lo G.-H.; Yang C.-C.; Lin C.-Y.; Lee P.-L.; Chien R.-N.; Wang J.-H.; Chen J.-J.; Tung S.-Y.; Hung C.-H.; Kuo H.-T.; Lai H.-C.; Tseng K.-C.; Chen C.-Y.; Hsu W.-F. |
